Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03190967
Recruitment Status : Recruiting
First Posted : June 19, 2017
Last Update Posted : April 8, 2021
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 30, 2022
Estimated Study Completion Date : June 30, 2023
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):